Buscar
Mostrando ítems 1-3 de 3
Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program
(Taylor & Francis, 2014-07-07)
[Abstract] BACKGROUND: Based on the TROPIC study results, cabazitaxel was approved for the management of metastatic castration-resistant prostate cancer (mCRPC) progressing on or after docetaxel.
METHODS: This multi-centre ...
MicroARN circulantes en sangre de pacientes con cáncer de próstata
(Elsevier, 2014)
[Resumen] Introducción. Los microARN (miARN) son ARN reguladores de pequeño tamaño que no codifican para proteínas. La detección de células tumorales circulantes (CTC) proporcionaría información diagnóstica y pronóstica ...
Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer
(American Association for Cancer Research, 2014-02-17)
[Abstract] PURPOSE: Figitumumab is a human IgG2 monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R), with antitumor activity in prostate cancer. This phase II trial randomized chemotherapy-naïve ...